BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline BRISBANE, ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

Gaze patterns vary substantially among people with varying levels of vision, pointing to the need for individualized rehabilitation strategies and assistive technologies, according to a study.

Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies The CHAI platform extracted quantitative histomorphologic features from whole-slide images of ...

Relative Energy Deficiency in Sport (REDs) has various different risk factors, numerous signs and symptoms and is heavily influenced by one’s environment. Accordingly, there is no singular validated ...

Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.

Linda McMaken has 15+ years of experience as a writer and editor. She is a published author and skilled blogger about consumer finance. Eric's career includes extensive work in both public and ...